<DOC>
	<DOCNO>NCT01193933</DOCNO>
	<brief_summary>1. evaluation blast clearance b/m 7 day prednisolone prephase efficacy substitution dexamethasone blast count 25 % 2. feasibility adult `` interruption '' protocol 8 week induction 14 week consolidation follow 2-years maintenance . 3. tolerability efficacy adult prolong L-asparaginase application ( total propose dose 560.000 IU ) 4. feasibility efficacy autologous stem cell transplantation T-cell ALL</brief_summary>
	<brief_title>Multicenter Clinical Trial Adult Ph-negative ALL . Continuous Treatment With Modification Cytostatic Drugs Doses Depending Myelosuppression Severity</brief_title>
	<detailed_description>1 . The blast count b/m 7 day prednisolone &gt; 25 % show 64 % patient . The substitution prednisolone dexamethasone influence survival . 2 . `` interruption '' induction perform 48 % patient . 3 . In 19 % patient L-asparaginase therapy stop due toxicity . 4 . Autologous stem cell transplantation do 20 % T-cell ALL patient .</detailed_description>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>Antineoplastic Agents</mesh_term>
	<criteria>Phnegative precursor ALL age 1555 year nontreated Eastern Cooperative Oncology Group criterion status 03 Bmature ALL Phpositivity pretreatment Eastern Cooperative Oncology Group criterion status 4</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>adult ALL</keyword>
	<keyword>Ph-negative</keyword>
	<keyword>dexamethasone</keyword>
	<keyword>L-asparaginase</keyword>
</DOC>